pleural mesothelioma
Conditions
Brief summary
Disease control rate (DCR) at 12 weeks, according to RECIST 1.1 criteria modified for mesothelioma, as assessed by an Independent Review Committee (IRC) of 3 expert thoracic radiologists and oncologists
Detailed description
Incidence, nature and severity of AEs, graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events, version 5.0 (NCI CTCAE v5.0), Progression free survival (PFS) as assessed by an IRC of 3 expert thoracic radiologists and oncologists, PFS as assessed by the local investigator, PFS according to previous immunotherapy versus no previous immunotherapy, PFS according to the histological subtype epithelioid vs. non-epithelioid, Overall survival (OS), Best response rate, Duration of response (DOR)
Interventions
DRUGivonescimab
Sponsors
Intergroupe Francophone De Cancerologie Thoracique
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Disease control rate (DCR) at 12 weeks, according to RECIST 1.1 criteria modified for mesothelioma, as assessed by an Independent Review Committee (IRC) of 3 expert thoracic radiologists and oncologists | — |
Secondary
| Measure | Time frame |
|---|---|
| Incidence, nature and severity of AEs, graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events, version 5.0 (NCI CTCAE v5.0), Progression free survival (PFS) as assessed by an IRC of 3 expert thoracic radiologists and oncologists, PFS as assessed by the local investigator, PFS according to previous immunotherapy versus no previous immunotherapy, PFS according to the histological subtype epithelioid vs. non-epithelioid, Overall survival (OS), Best response rate, Duration of response (DOR) | — |
Countries
France
Outcome results
None listed